TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immune Response to the COVID-19 Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have active solid tumor malignancy diagnosis~2. On active chemotherapy~3. Received two prior SARS-COV2 Pfizer vaccines~4. Age ≥ 18 years~5. Ability to understand and the willingness to sign a written informed consent~6. Agree to comply with study procedures~7. Subjects previously enrolled under the main study~Exclusion Criteria:~1. History of HIV or organ/bone marrow transplant~2. Actively receiving immunotherapy~3. On active, chronic immunosuppression (\>10 mg daily dose of prednisone equivalent)~4. Currently incarcerated or residence of another state~5. Speaks a language other than English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3rd COVID-19 vaccine (2nd booster) (Type: EXPERIMENTAL): Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of TENS for Pain and Function After Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary osteoarthritis of the knee~* Speak English~* Unilateral total knee replacement~Exclusion Criteria:~* No ambulation, assisted or otherwise~* Use of TENS by subject in past 5 yrs~* Current use of TENS by someone else in subject's household~* Stroke or other condition which seriously impairs sensation in legs or ability to follow directions.~* Condition that precludes use of TENS (pacemaker, allergy to nickel, etc.)~* Chronic pain (other than in surgical knee) that is currently being treated or is severe. (Do not exclude for fibromyalgia).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Active TENS (Type: ACTIVE_COMPARATOR): High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
- Placebo TENS (Type: PLACEBO_COMPARATOR): Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working.
- Standard Care (Type: NO_INTERVENTION): Subjects randomized to Standard Care will be given no TENS unit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* severe hoarseness~* vocal fold scarring~* no active other treatment~* age above 18 years~Exclusion Criteria:~* active treatment of laryngeal disorder~* active inflammatory condition of the larynx~* diagnosed or suspicions of local malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aMSC with and without hyaluronan gel (Type: EXPERIMENTAL): autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Young girls with turner syndrome proved by karyotype~* Growth hormone secretion confirmed with ornithin stimulation test~* Normal glucidic metabolism confirmed by assessment of HbA1c~* None associated severe pathology which could have impact on growth (i.e. renal insufficiency, decompensated heart failure)~* No previous or associated treatment with anabolic or sexual steroids~* Known parental height~Exclusion Criteria:~* Severe associated pathology with impact on growth~* Concomitant treatment with impact on growth~* Previous or associated treatment with anabolic steroids~* Associated growth hormone deficiency

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- r-hGH (Type: EXPERIMENTAL): Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
- Historical Control (Type: NO_INTERVENTION): This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of 5 Low Volume Bowel Preparations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years old planning to undergo an elective colonoscopy will be eligible for inclusion in our study. We would prefer to exclude as few groups as possible since in clinical practice these less well studied groups often need a colonoscopy and will need to have a colonoscopy preparation.~Exclusion Criteria:~1. Patients who are allergic (this is very rare) or intolerant to any of the study drugs.~2. Patients who are pregnant.~3. Patients who required multiple day colon preparations (2 days prior and 1 day prior) in the past will be excluded.~4. Patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon would not be considered elective colonoscopies and are excluded.~5. Patients with known renal disease (baseline creatinine greater than 1.50 mg/dl) will need to be excluded due to the magnesium in SUPREP which is contraindicated in patients with significant renal disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MiraLAX 306 g (Day-Prior) (Type: ACTIVE_COMPARATOR): MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 51 g at 12 noon; Gatorade 64 oz mixed with Miralax 255 g from about 6 PM to 9 PM
- MiraLAX 357 g (Day-Prior) (Type: EXPERIMENTAL): MiraLAX 357 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 68 g at 12 noon; Gatorade 64 oz mixed with Miralax 289 g from about 6 PM to 9 PM.
- MiraLAX 306 g (Split-Dose) (Type: EXPERIMENTAL): MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed as a split-dose as follows: Gatorade 32oz mixed with Miralax 153 g from about 6 PM to 8 PM the day prior to the colonoscopy; Gatorade 32oz mixed with Miralax 153 g from about 2-4 hours prior to the colonoscopy.
- MoviPrep (Split-Dose) (Type: ACTIVE_COMPARATOR): MoviPrep consumed as a split-dose as follows: MoviPrep 1 liter consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 0.5 liter of clear liquids; MoviPrep 1 liter consumed from 3-4 hours prior to the colonoscopy followed by 0.5 liter of clear liquids.
- SUPREP (Split-Dose) (Type: ACTIVE_COMPARATOR): SUPREP consumed as a split-dose as follows: SUPREP 16 oz consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 32 oz of clear liquids; SUPREP 16 oz consumed from 3-4 hours prior to the colonoscopy followed by 32 oz of clear liquids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Use of Dexketoprofen/Tramadol for Acute Postoperative Pain in Total Hip Replacement With a Direct Anterior Approach.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* unilateral total hip arthroplasty with a direct anterior minimal invasive technique~* ASA score I or II~* signed written informed consent form~* 3 days hospitalization~* 45-80 years old~* primary Total hip arthroplasty~Exclusion Criteria:~* allergy to any given drugs~* contraindications for spinal anesthesia~* active bleeding~* renal failure ( gfr\< 90ml/h)~* hepatic failure ( abnormal sgot,sgpt,γgt)~* heart failure~* history of gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Group A was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.~Group A was given the oral combination dexketoprofen/tramadole (25mg/75mg) 2h after surgery every 8h for 72h.
- Group B (Type: PLACEBO_COMPARATOR): Group B was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.~Group B received postoperative analgesia with intravenous tramadole 75mg and paracetamol 1g every 8h with the first dose beginning 2h after the end of the surgery. For 72h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development of Positive Psychotherapy for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* smoke at least 5 cigarettes per day for longer than one year with no other ongoing tobacco product use~* willing to use the transdermal nicotine patch~* report at least a 5 on a 0 to 10 scale rating the importance of quitting smoking.~Exclusion Criteria:~* are currently experiencing psychotic symptoms, affective disorder (major depression, dysthymia, or mania) or substance use disorder (other than nicotine dependence)~* taking prescribed psychotropic medication or receiving other forms of psychotherapy~* concomitantly using other pharmacotherapies for smoking cessation~* have any contraindications for use of the transdermal nicotine patch.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Positive psychotherapy (Type: EXPERIMENTAL): 6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
- Standard treatment (Type: ACTIVE_COMPARATOR): 6 sessions of individual behavioral smoking cessation counseling with 8 weeks of transdermal nicotine patch. Inlcudes relaxation training to match time in the experimental condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All women completing NCT01440803 who remain without a disease or medication that causes osteoporosis will be offered enrollment into this study.~* (Premenopausal status is no longer be required for entry.)~Exclusion Criteria:~* Renal insufficiency or liver disease: Creatinine, transaminase (AST)/alanine transaminase (ALT) above upper limit of normal~* Vitamin D deficiency: 25-hydroxyvitamin D (25-OHD) \<30 ng/mL~* Pregnancy: urine pregnancy test must be negative

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Detection and Intervention for the Prevention of Psychosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects in the age range of 12-25 and living in the experimental catchment area may be enrolled in the EDIPP study based on meeting at least one of the inclusion requirements AND none of the exclusion criteria;~* Screening process indicates symptoms equivalent to a minimum rating of '1' on at least one positive symptom of psychosis;~* Screening process indicates a likely family history of first degree relative with psychotic illness plus a deterioration in functioning equivalent to a 30% drop in functioning score over the past year; OR~* Screening process indicates a likely history of schizotypal personality disorder plus a deterioration in functioning equivalent to a 30% drop in functioning over the past year.~Exclusion Criteria:~* Outside the age range of 12 to 25 years;~* History of intelligence quotient (IQ) below 70 (based on school records, not tested at PIER);~* More than one month duration of psychosis (guided by the criteria of at least one 6 on the Positive Symptom sub-scale of the Scale of Positive Symptoms (SOPS);~* History of previous psychotic episode, whether or not treatment was received;~* Taken antipsychotic medication for more than 30 days at a therapeutic dose for psychotic symptoms;~* Either the young person being screened for the study or both parents do not speak proficient English;~* Female is pregnant at baseline (inquired on the screening interview); AND~* Subject is a prisoner.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): This is the control arm. Participants will be offered only case management. Participants may seek outside treatment, without guidance from study staff.
- Family-aided Assertive Community Treatment (Type: EXPERIMENTAL): This is the experimental intervention arm for high-risk-for-psychosis participants. The intervention includes psychiatric drugs (aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine), psychoeducational multifamily group treatment and supported employment and education .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Right-handed subjects~* Ability and willingness to participate in the study~* Ability to provide written informed consent~* Informed Consent as documented by signature~* Schizophrenia spectrum disorder according to diagnostic and statistical manual version 5 (DSM-5) criteria with current psychomotor slowing according to the Salpetriere Retardation Rating Scale (SRRS), score \>= 15~Exclusion Criteria:~* Substance abuse or dependence other than nicotine~* Past or current medical or neurological condition associated with impaired or aberrant movement, such as brain tumors, stroke, M. Parkinson, M. Huntington, dystonia, or severe head trauma with subsequent loss of consciousness.~* Epilepsy or other convulsions~* History of any hearing problems or ringing in the ears~* Standard exclusion criteria for MRI scanning and TMS; e.g. metal implants, claustrophobia~* Patients only: any TMS treatment in the past 3 months~* Women who are pregnant or breast feeding,~* Intention to become pregnant during the course of the study,~* Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.~* Previous enrolment into the current study,~* Enrolment of the investigator, his/her family members, employees and other dependent persons~* Controls only: history of any psychiatric disorder or first-degree relatives with schizophrenia spectrum disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Inhibitory repetitive transcranial magnetic stimulation (rTMS) (Type: EXPERIMENTAL): 1 Hz stimulation of 17 mins over the supplementary motor area (SMA), 1000 pulses at 110% resting motor threshold intensity total of 15 sessions in 3 weeks
- Facilitatory intermittent theta burst stimulation (iTBS) (Type: ACTIVE_COMPARATOR): Intermittent theta burst stimulation of 50 Hz over the supplementary motor area (SMA) with 600 pulses in 2 sec trains every 10 seconds for 190 seconds total. Two iTBS stimulations will be administered with 15 mins pause in between.~total of 15 sessions in 3 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 1 Hz stimulation of 17 mins over the supplementary motor area (SMA) without any magnetic emission using a placebo-coil that looks identical and makes identical sounds as the real TMS coil total of 15 sessions in 3 weeks
- Waiting group (Type: NO_INTERVENTION): This group will receive no intervention for 3 weeks. Afterwards they will receive the inhibitory rTMS protocol as in the first arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* moderate to severe hypertension~* 3 additional risk factors such as age \> 55 (male), \> 65 female, smoker, type 2 diabetes, obesity, cardiovascular disease, congestive heart failure, chronic kidney disease,~* ability to give informed consent~Exclusion Criteria:~* secondary or malignant hypertension~* contraindication to any of the study drugs~* Creatinine clearance level \<40ml/min~* treatment with more than 3 antihypertensive drugs~* Myocardial infarction, percutaneous transluminal coronary angioplasty, cardiac bypass surgery \< 6 month prior to start of the study,~* unstable angina pectoris,~* stroke, transient ischemic attack \< 3 months prior to start,~* Congestive heart failure NYHA II-IV,~* clinically relevant concomitant diseases,~* alcohol or drug abuse,~* pregnancy or women of childbearing potential without contraceptive precaution,

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Perindopril+amlodipine (Type: ACTIVE_COMPARATOR): None
- Olmesartan/amlodipine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete